Breaking AI Chatbots Emerge as New Spiritual Guides Amidst Growing Demand Los Angeles Rams Conclude Undefeated Preseason With Victory Over Chargers Tulane University to Redevelop Historic Charity Hospital Site into $500 Million Research Facility Civil Rights Leaders Rally on National Mall for Voting Rights and Racial Justice Ahead of Midterms President Trump Alters Stance on U.S.-Iran War, Cites Sanctions Amid Munitions Concerns

Friday August 28, 2026

Reporter

Revolution Medicines, Inc.

4Articles Published

4Communities Covered

Published Articles

Press Release

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Aug 26

Press Release

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Aug 5

Press Release

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

Jul 29

Press Release

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

Jul 22